- N-methylglucamine
-
- $1.00 / 500g
-
2025-10-18
- CAS:6284-40-8
- Min. Order: 300g
- Purity: 99.8%
- Supply Ability: 20 TONS
- Meglumine
-
-
2025-10-18
- CAS:6284-40-8
- Min. Order:
- Purity: 0.99
- Supply Ability:
- Meglumine
-
- $0.00 / 25kg
-
2025-10-17
- CAS:6284-40-8
- Min. Order: 1kg
- Purity: 99%min
- Supply Ability: 500kgs
|
| | Meglumine Basic information |
| | Meglumine Chemical Properties |
| Melting point | 129-131.5 °C (lit.) | | alpha | -16.5 º (c=10, H2O, on dry sub) | | Boiling point | 331.88°C (rough estimate) | | density | 1.2669 (rough estimate) | | bulk density | 300kg/m3 | | refractive index | -16.5 ° (C=2, H2O) | | RTECS | LZ4295770 | | storage temp. | 2-8°C | | solubility | H2O: 0.1 g/mL, clear, colorless | | form | Crystalline Powder | | pka | pKa 9.39(H2O,t =30.0,I=0.05N2)(Approximate) | | color | White to almost white | | PH | 11 (10g/l, H2O, 20℃) | | biological source | synthetic (organic) | | Optical Rotation | [α]20/D 16.5±0.5°, c = 2% in H2O | | Water Solubility | 100 g/100 mL (25 ºC) | | Sensitive | Air Sensitive & Hygroscopic | | Merck | 14,6078 | | BRN | 385906 | | InChIKey | MBBZMMPHUWSWHV-VZFHVOOUSA-N | | LogP | -3.370 (est) | | NIST Chemistry Reference | N-methylglucamine(6284-40-8) | | EPA Substance Registry System | Meglumine (6284-40-8) |
| Risk Statements | 36/37/38 | | Safety Statements | 24/25 | | WGK Germany | 3 | | F | 3-10-23 | | Autoignition Temperature | ~662 °F | | TSCA | Yes | | HS Code | 29221980 | | Toxicity | LD50 orally in Rabbit: > 5000 mg/kg |
| | Meglumine Usage And Synthesis |
| Chemical Properties | white to almost white crystalline powder | | Chemical Properties | Meglumine occurs as a white to slightly yellow-colored crystalline
powder; it is odorless or with a slight odor. | | Uses | antiinflammatory | | Uses | excipient in cosmetics and X-ray contrast media | | Uses | N-Methyl-D-glucamine is used in conjunction with iodinated organic compounds in contrast media viz. diatrizoate meglumine and iodipamide meglumine. It is useful in ion-exchange resins to chelate boron ions selectively. It is also used as an excipient in pharmaceuticals, in cosmetics and X-ray contrast media. It is also employed in the synthesis of surface active agents, pharmaceuticals and dyes. | | Production Methods | Meglumine is prepared by the imination of glucose and monomethylamine,
in an alcoholic solution, followed by catalytic
hydrogenation. | | Definition | ChEBI: A hexosamine that is D-glucitol in which the hydroxy group at position 1 is substituted by the nitrogen of a methylamino group. A crystalline base, it is used in preparing salts of certain acids for use as diagnostic radiopaque media, whi
e its antimonate is used as an antiprotozoal in the treatment of leishmaniasis. | | Brand name | Renovue
(Bracco). | | General Description | Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.
Meglumine is a glucose-derived secondary amine which is widely used as an excipient in pharmaceutical formulations. | | Pharmaceutical Applications | Meglumine is an organic base used as a pH-adjusting agent and
solubilizing agent, primarily in the preparation of soluble salts of
iodinated organic acids used as X-ray contrast media. | | Safety | Meglumine is widely used in parenteral pharmaceutical formulations
and is generally regarded as a nontoxic material at the levels
usually employed as an excipient.
LD50 (mouse, IP): 1.68 g/kg | | storage | Meglumine does not polymerize or dehydrate unless heated above
150°C for prolonged periods.
The bulk material should be stored in a well-closed container in a
cool, dry place. Meglumine should not be stored in aluminum
containers since it reacts to evolve hydrogen gas; it discolors if
stored in containers made from copper or copper alloys. Stainless
steel containers are recommended. | | Purification Methods | Crystallise N-methyl-D(-)-glucamine from MeOH. Its solubility in H2O is 10%. [Karrer & Herkenrath Helv Chim Acta 20 83 1957 also for other N-alkyl derivatives, Beilstein 4 IV 1914.] | | Incompatibilities | Incompatible with aluminum, copper, mineral acids, and oxidizing
materials. Differential scanning calorimetry studies suggest meglumine
is incompatible with glipizide. | | Regulatory Status | Included in the FDA Inactive Ingredients Database (injections; oral
tablets). Included in parenteral medicines licensed in the UK. | | References | [1] Patent: US2014/255330, 2014, A1. Location in patent: Paragraph 0207
[2] Patent: US1994467, 1932,
[3] Helvetica Chimica Acta, 1937, vol. 20, p. 83,85
[4] Chemische Berichte, 1966, vol. 99, p. 812 - 822
[5] RSC Advances, 2014, vol. 4, # 10, p. 5152 - 5155 |
| | Meglumine Preparation Products And Raw materials |
|